New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
Posters
High Quality Whole Transcriptome RNA-Sequencing from Challenging Clinical Samples
June 23, 2025
More infoPosters
Performance Evaluation of an Ultra-Sensitive Assay for NSCLC Biomarker Testing
June 23, 2025
More infoCellTalk Blog
CROs vs. CMOs vs. CDMOs: Understanding the Differences in Outsourcing Partners
June 10, 2025
More infoCellTalk Blog
What is a Contract Research Organization (CRO), and How Do You Choose the Right One?
June 4, 2025
More info